Health
Obesity Drug Wegovy Cuts Risk of Heart Attacks and Strokes by 20%, Study Shows
- Study finds 20% reduction in heart attacks and strokes
- Eli Lilly raises outlook after strong sales of rival drug
This article is for subscribers only.
Novo Nordisk A/S’s blockbuster obesity medicine Wegovy reduced the risk of heart attacks and strokes in a highly anticipated study, buoying shares of the Danish drugmaker and the US maker of a potential rival treatment, Eli Lilly & Co.
People with obesity or overweight and a history of heart issues taking the Novo drug were 20% less likely to suffer a cardiovascular event than those who took a placebo, the Danish drugmaker said on Tuesday.